Q&A: Aviv Regev talks three years at Genentech, future of AI in biotech

SOUTH SAN FRANCISCO — In 2020, Aviv Regev ended an esteemed 14-year run at the Broad Institute to jump into the drug industry, becoming Genentech’s head of research and early development.

The 52-year-old computational biologist has pioneered the field of single-cell genomics, which studies individual cells at massive scale, weaving together…
Click here to view original post